Epilepsy drug shows potential for Alzheimer's treatment

Dec 08, 2008

A drug commonly used to treat epilepsy could help clear the plaques in the brain associated with Alzheimer's disease, according to researchers at the University of Leeds. The plaques are known to lead to the progressive death of nerve cells in the brain linked to many forms of dementia.

Sodium valproate - which is marketed as the anti-seizure drug Epilim - has been shown by scientists at the University of Leeds to reactivate the body's own defences against a small protein called amyloid beta peptide, which is the main component of the brain plaques characteristic in Alzheimer's. Their work was funded by the Medical Research Council.

"The fact that we've been able to show that a well-established, safe and relatively inexpensive drug could help treat Alzheimer's is an extremely exciting development," says lead researcher Professor Tony Turner from the University's Faculty of Biological Sciences. "We hope colleagues will be able to progress this research with clinical trials in the near future."

Alzheimer's disease is the most common form of dementia and has no cure. In the UK today there a half a million people living with Alzheimer's – and this is likely to double within a generation unless new treatments are found.

Sodium valproate has been used for many years to suppress epileptic seizures and the many sufferers of epilepsy have been taking the drug for decades with few side effects.

The development of Alzheimer's is widely believed to be caused by the gradual accumulation in the brain of amyloid-beta peptide which is toxic to nerve cells. This is thought to be caused by a key enzyme called neprilysin or NEP gradually switching off in later life. One of NEP's roles is to clear the toxic peptide from the brain, and plaques begin to form as it gradually switches off, leading to the death of the brain's nerve cells.

The research team examined changes in chromatin – the 'packaging' that genes are contained within - and surmised that these changes might be involved in switching off NEP. The team found clear differences (acetylation) in key proteins within the chromatin when they compared normal nerve cells against those that failed to produce NEP.

"From there it was relatively simple to stimulate the expression of NEP with sodium valproate, which was seen to prevent the acetylation," says Professor Turner. "We were elated when we saw the results."

Source: University of Leeds

Explore further: Added benefit of vedolizumab is not proven

add to favorites email to friend print save as pdf

Related Stories

US charges safari owners with illegal rhino hunts

55 minutes ago

Two South African men were charged Thursday by the US government with conspiracy to sell illegal rhinoceros hunts to American hunters, money laundering and secretly trafficking in rhino horns.

Close encounters: Comet siding spring seen next to mars

1 hour ago

(Phys.org) —This composite NASA Hubble Space Telescope Image captures the positions of comet Siding Spring and Mars in a never-before-seen close passage of a comet by the Red Planet, which happened at 2:28 ...

Recommended for you

Added benefit of vedolizumab is not proven

23 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

zecoseco
not rated yet Apr 29, 2009
good